Barclays Starts Cellectis (CLLS) at Overweight May 28, 2026 03:43AM
Cellectis (CLLS) Tops Q1 EPS by 8c May 11, 2026 04:45PM
Cellectis (CLLS) Reiterated at Market Outperform by Citizens After MRD Clearance Apr 14, 2026 05:05AM
Cellectis (CLLS) Reiterated at Market Outperform by Citizens: 2025 Pipeline Updates Good Mar 23, 2026 04:47AM
Jefferies Assumes Cellectis (CLLS) at Buy Feb 17, 2026 02:41AM


Dec 22, 2025 04:21PM Clear Street Starts Cellectis (CLLS) at Buy
Dec 15, 2025 05:40PM Allogene retains control of cancer therapy after arbitration ruling
Dec 15, 2025 04:53PM Cellectis receives arbitral decision in Servier licensing dispute
Nov 21, 2025 07:30AM Moligo Technologies and Cellectis publish gene editing research in Nature
Nov 19, 2025 06:19AM Cellectis publishes gene editing research in Nature Communications
Nov 18, 2025 04:24AM Cellectis' (CLLS) OpEx to Fund Operations into 2027 - Citizens
Oct 17, 2025 05:10AM Cellectis (CLLS) PT Raised to $6 at Jefferies
Oct 17, 2025 05:05AM Cellectis (CLLS) PT Raised to $8 at Barclays
Oct 16, 2025 03:24PM Cellectis reports Phase 1 data for leukemia therapy lasme-cel
Aug 4, 2025 04:32PM Cellectis (CLLS) Misses Q2 EPS by 2c
Jun 4, 2025 04:19PM Cibus, Inc. (CBUS) Announces Proposed Public Offering
May 13, 2025 07:13AM Cellectis (CLLS) Tops Q1 EPS by 7c
Mar 14, 2025 05:39AM Cellectis (CLLS) Misses Q4 EPS by 7c
Nov 5, 2024 01:08PM Baird Reiterates Outperform Rating on Cellectis (CLLS)
Nov 4, 2024 07:26PM Cellectis (CLLS) Misses Q3 EPS by 3c
Sep 18, 2024 08:26AM Cibus (CBUS) Prices 3M Share Public Offering of Class A Common Stock at $4/Each
Sep 17, 2024 04:46PM Cibus (CBUS) Announces Proposed Public Offering of Class A Common Stock
Aug 6, 2024 06:20PM Cellectis (CLLS) Tops Q2 EPS by 1c
Jun 12, 2024 07:45AM Cellectis (CLLS) PT Lowered to $10 at Oppenheimer